• GENB share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of GENB shares has increased $0.49 since the market last closed. This is a 3.90% rise.

  • Closed at $13.06.

    The stock has since risen $0.08 in after-hours trading.

Key terms

About GENB

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $1.68B

    A market capitalization between $300 million and $2 billion places GENB in the small capitalization category.

Key terms

Smart score

Latest GENB news

Oct 29, 2026 8:55am ET Kapoor Reiterates Buy on Generate Biomedicines, Keeping $30 Price Target Amid Encouraging CAR-T and Anthropic AI Progress by TipRanks Oct 16, 2026 4:40pm ET Generate Biomedicines management to meet with Cantor by TipRanks Oct 14, 2026 11:45am ET Generate Biomedicines: Zealand Partnership Expands Metabolic Pipeline as Analyst Reiterates Buy and Maintains $30 Price Target by TipRanks Oct 14, 2026 7:26am ET Piper Sandler Keeps Their Buy Rating on Generate Biomedicines, Inc. (GENB) by TipRanks Oct 13, 2026 4:40pm ET Generate Biomedicines, Zealand Pharma enter protein therapeutics pact by TipRanks Oct 05, 2026 6:45am ET Generate Biomedicines: Buy Rating Reiterated as Platform and Pipeline Progress Support Unchanged $30 Price Target by TipRanks Oct 02, 2026 8:36am ET Seven new option listings on October 2nd by TipRanks Oct 02, 2026 7:30am ET Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK) by TipRanks Sep 08, 2026 1:00pm ET Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB) by TipRanks Aug 28, 2026 6:10am ET Generate Biomedicines price target raised to $30 from $25 at H.C. Wainwright by TipRanks Aug 26, 2026 12:05pm ET Generate Biomedicines falls -16.7% by TipRanks Aug 26, 2026 10:05am ET Generate Biomedicines falls -11.0% by TipRanks Aug 25, 2026 12:06pm ET Generate Biomedicines rises 17.7% by TipRanks Aug 17, 2026 8:57am ET Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB) by TipRanks Aug 07, 2026 8:09am ET Piper Sandler Remains a Buy on Generate Biomedicines, Inc. (GENB) by TipRanks Aug 07, 2026 6:46am ET Generate Biomedicines Reaffirmed at Buy as GB-0895 Progress and Cash Runway Support Unchanged $25 Price Target by TipRanks Aug 06, 2026 8:06am ET Generate Biomedicines reports Q2 EPS (52c), consensus (49c) by TipRanks
Oct 22, 2026 7:00am ET Generate Biomedicines to Participate in November Investor Conferences by GlobeNewswire Oct 13, 2026 4:30pm ET Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases by GlobeNewswire Sep 08, 2026 7:09am ET Generate Biomedicines Inc. to Participate in September Investor Conferences by GlobeNewswire Aug 06, 2026 7:00am ET Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update by GlobeNewswire

GENB Financials

1-year income & revenue

  • GENB total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • GENB net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • GENB earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

GENB Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

GENB Competitors

$ Market capP/E ratio$ Price1d change52-week range
  • How competitors are chosen

    GENB's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $1.68B

    A market capitalization between $300 million and $2 billion places GENB in the small capitalization category.

Key terms

Latest investing news